GeneThera Issues February Letter to Shareholders and Updates Activities

        Print
| Source: GeneThera, Inc.

WHEAT RIDGE, Colo., Feb. 9, 2009 (GLOBE NEWSWIRE) -- GeneThera, Inc. (Pink Sheets:GTHR), a leading international biotechnology company dedicated to improving food safety, announced its February Letter to Shareholders summarizing recent activity and corporate events.

GeneThera's primary product is an extraordinarily sensitive proprietary diagnostic solution with high concentrations of genetic particles. It was developed in response to the urgent need for fast, inexpensive, reliable live-assay (non-destructive) testing of farm and game animals for Mad Cow, Chronic Wasting and other diseases. In combination with GeneThera's proprietary system for analyzing large amounts of data, the diagnostic solution provides for completion of testing in a very short time.

Translation...


 * Entire herds of animals won't need to be slaughtered, resulting in
   significant cost savings for clients

 * Loss of fewer animals over time, because testing can be done at 
   regular intervals

 * Easy field collection system to gather samples and insure sample
   integrity and consistency

 * Low cost testing and analysis technologies, which make it affordable
   for all farmers and ranchers

In our move from a Research and Development Company we have been approached by several large firms who are interested in distribution of our product, as it is one of the most efficient solutions on the market for testing farm and/or game animals. We are carefully reviewing our available options for a distribution agreement or agreements. In order for us to test millions of animals clearly we need a solid partner and these deals do not happen overnight. We will make every effort possible to update you on these partnerships as they develop.

We have also looked at acquiring the next set of major biotech breakthroughs. Currently, we are in discussions with three private companies who have products, which are ready to be marketed or are in the final stages of clinical trials. All of these companies have capital already available to them, but require the contacts to get their products to market. I have chosen to not issue or sign any Letter of Intents until we are at near certainty in completing the transactions (i.e. financial review, inventory, and post-merger plans).

The re-audit of our financials should be complete in February. The complete audit of our financials is a requirement for any potential merger. Also, by completing the audit it would also make GTHR qualified to move to a higher exchange if we chose to stay independent.

Our website is currently being revamped and will be updated soon. This is being done in conjunction with our packaging contract with the Stephen Gould Corporation.

At this time I would like to thank those who have supported our business efforts and encouragement to receive a nomination for the National Advisory Committee on Meat and Poultry. It has been my passion and my pleasure to serve the biotech community representing the farm industry in America. If selected I will continue to serve in a capacity which will ensure the safety of the American Consumer.



 Anthony (Tony) Milici, MD PHD
 GeneThera President and CEO

ABOUT GENETHERA, INC.

GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne's disease. For more information, contact Dr. Tony Milici at 303-463-6371 or Al Goldsmith of The Goldsmith Group LLC at 303-838-4370.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

GeneThera, Inc.
Dr. Tony Milici
303-463-6371

Goldsmith Group
303-838-4370

JR Dopkin & Associates
516-884-3200